Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / Hawaii

Peptide legality · Hawaii · updated 2026-09-21

Are peptides legal in Hawaii?

Gray area

Hawaii permits peptide therapy under the federal framework, meaning FDA-approved peptides are legal by prescription while compounded and research peptides sit in a gray zone driven by FDA rules rather than a Hawaii-specific ban.

Legal status overview

Hawaii permits peptide therapy under the federal framework and has not enacted peptide-specific restrictions of its own. FDA-approved peptide medicines such as Wegovy® (semaglutide) are legal when prescribed by an authorized provider, and compounded peptides are available through licensed pharmacies only under limited conditions. Compounded medications are not FDA-approved, are not a generic, and have not been evaluated by the FDA. BPC-157 and similar research peptides remain in federal regulatory limbo after the FDA removed BPC-157 from Category 2 in April 2026 without adding it to the 503A bulk substances list. This is information, not medical or legal advice.

Key points

  • Hawaii has no peptide-specific statute, so legality follows the federal FD&C Act framework administered by the Hawaii Board of Pharmacy under the DCCA and the FDA. [2]
  • FDA-approved peptide products including Wegovy® (semaglutide) are legal in Hawaii when prescribed by providers such as an MD, DO, NP, APRN, or PA under supervision. [3]
  • The FDA resolved the semaglutide shortage in February 2025, and 503A enforcement discretion for compounded copies ended April 22, 2025, limiting lawful compounding to documented clinical need. [1]
  • Compounded GLP-1 medicines are available in Honolulu and statewide only through licensed pharmacies under narrow conditions, and compounded medications are not FDA-approved, not a generic, and not evaluated by the FDA. [6]
  • BPC-157 was removed from FDA Category 2 effective April 23, 2026, yet has not been added to the Section 503A Category 1 list, leaving its compounding status unresolved. [4]
  • A July 2026 FDA advisory committee vote recommended adding several peptides including BPC-157 to the 503A list, but the recommendation is non-binding and did not authorize compounding on its own. [5]
  • Growth hormone peptides and FDA-approved peptide medicines are accessible in Hawaii through licensed 503A pharmacies with a valid prescription and provider relationship. [7]
  • Hawaii is not among the states that issued their own restrictive board guidance on compounded GLP-1s or peptides, so the federal floor governs. [2]

Compound-by-compound status

BPC-157
Gray area
Removed from FDA Category 2 in April 2026 but not yet on the Section 503A bulk substances list; a July 2026 advisory vote to add it is non-binding, so lawful compounding remains uncertain.
GLP-1 class, for example Wegovy® (semaglutide) and Zepbound® (tirzepatide)
Gray area
FDA-approved brands are legal by prescription; compounded copies are restricted after the shortage resolution and allowed only for documented clinical need. Compounded versions are not FDA-approved, not a generic, and not evaluated by the FDA.
TB-500 (thymosin beta-4)
Gray area
Not FDA-approved and not on the 503A bulk substances list, so it sits in the same federal compounding limbo as other research peptides.
Growth hormone / somatropin
Restricted
FDA-approved by prescription, but federal law limits human growth hormone distribution to FDA-approved indications, making off-label supply restricted.

Frequently asked questions

Are peptides legal in Hawaii?

There is no Hawaii law banning peptides. FDA-approved peptides are legal with a prescription, while compounded and research peptides depend on evolving FDA compounding rules rather than a state ban.

Can I get compounded semaglutide in Hawaii?

Only for a documented clinical reason after the FDA resolved the shortage. Compounded semaglutide is not FDA-approved, not a generic, and not evaluated by the FDA.

Is BPC-157 legal in Hawaii?

BPC-157 is in a federal gray zone. It was removed from FDA Category 2 in April 2026 but is not yet on the 503A bulk substances list, so its compounding status is unsettled, including in Hawaii.

Who can prescribe peptides in Hawaii?

Providers such as MDs, DOs, nurse practitioners, APRNs, and physician assistants with appropriate supervision may prescribe, consistent with Hawaii licensing rules.

Where can I fill a peptide prescription in Hawaii?

Through pharmacies licensed by the Hawaii Board of Pharmacy, including compounding pharmacies serving Honolulu and the neighbor islands, with a valid prescription.

General information based on the sourced research above, not legal advice. For a specific situation in Hawaii, consult a licensed attorney familiar with pharmaceutical law.